Zenotech Laboratories Ltd Share Price Today - Zenotech Laboratories Ltd Stock Price Live NSE/BSE

Zenotech Laboratories Ltd

NSE: BSE: 532039

₹42.84

(2.00%)

Tue, 17 Mar 2026, 11:48 pm

MTF 5xInvest in Zenotech Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap2.56B

PE Ratio79.03

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Zenotech Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
247.72
Net Profit
5.61
P/B
4.03
Sector P/E
39.71
P/E
0
EV/EBITDA
0
Debt/Equity (Industry)
0.25
Interest Cover (Industry)
11.42
ROCE (Industry)
16.55
RONW (Industry)
14.50
ROE
0
ROCE
0
Debt/Equity
0.13
EPS (TTM)
0.60
Dividend Yield
0
Book Value
15.77
Interest Cover
-5.40

Analysis

all

Pros

Zenotech Laboratories is profitable, therefore cash runway is not a concern.
Zenotech Laboratories is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (61%, greater than 20% of total debt).
Zenotech Laboratories's cash and other short term assets cover its long term commitments.
Zenotech Laboratories had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.

Cons

Unable to evaluate Zenotech Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Zenotech Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Zenotech Laboratories's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Debt is not covered by short term assets, assets are 0.3x debt.
High level of physical assets or inventory.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	68.84	68.84	68.84	68.84	68.84
FII	0	0	0	0	0
DII	0.01	0.01	0.01	0.01	0.01
Public	30.17	30.17	30.17	30.17	30.17
Government	0.98	0.98	0.98	0.98	0.98

Technical Analysis

RSI

38.91

MACD

-1.40

50 DMA

45.17

200 DMA

52.20

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	55.03	50.19	47.66	45.35	42.82	40.51	35.67
Fibonacci	50.19	48.34	47.20	45.35	43.50	42.36	40.51
Camarilla	46.45	46.01	45.56	45.35	44.68	44.23	43.79

Pivots Level: Classic

+9.68

55.03

+4.84

50.19

+2.30

47.66

45.35

Pivot Point

LTP: 40.59

-2.54

42.82

-4.84

40.51

-9.68

35.67

Moving Average

SMAEMA

Period

Value

10-EMA
41.81
20-EMA
43.06
30-EMA
43.78
50-EMA
44.78
100-EMA
46.98
200-EMA
50.99

Announcement Date	Purpose	Action	Ex Date
23 Jan 2026	board-meetings	Quarterly Results
31 Oct 2025	board-meetings	Quarterly Results
28 Jul 2025	agm
23 Aug 2024	agm
01 Sept 2023	agm
29 Aug 2022	agm
02 Sept 2021	agm
02 May 2017	rights	Right Issue of Equity Shares	02 Jun 2017

Zenotech Laboratories Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Cipla Ltd

Divis Laboratories Ltd

Zenotech Laboratories Ltd About

Zenotech Laboratories is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anaesthesiology.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1989

Headquarters

CEO

Employees

Contact

Website

http://www.zenotechlab.com

abdul.gafoor@zenotech.co.in

Phone

91-40-23480430/0435

Location

S No 250-252 Turkapally Villag, Shameerpet Mandal RR District, Hyderabad, Telangana, 500078

Year	History
2006	Zenotech Laboratories enters into strategic alliance with the Ranbaxy
2008	Zenotech Laboratories has Appointed Mr. Atul Sobti, Mr. Omesh Sethi and Mr. Dipak Chattraj as Non-Executive Directors of the Company
2011	Mr. I Srinivas has been appointed as Company Secretary cum Compliance officer of the company Dr. Sudershan K. Arora has been appointed as Executive Chairman of the Company. Registered Office of the Company has been shifted To Survey No. 250-252, Turkapally Village,Shameerpet Mandal,R.R.District -500078,Andhra Pradesh.
2013	Mr. Chinmoy Patnaik, Company Secretary and Head of Legal of the Company has been appointed as the Compliance Officer of the Company.
2017	The company issued rights shares of Rs. 10 in the ratio of 17:22 at a premium of Rs. 35 per share.

Client Name	Order Side	QTY	Avg Price	Date
DEUTSCHE TRUSTEE SERVICES (I) PRIVATE LIMITED	Buy	222316	107.05	15 Jul 2009

Zenotech Laboratories Ltd News

Zenotech Labs Appoints Independent Director

Zenotech Laboratories successfully appointed Mr. Nikkhil Venilal Kothhari as Independent Director through postal ballot with 99.90% approval from shareholders on March 11, 2026.

12 Mar 2026

stocks

Zenotech Labs Q3FY26 Results & Board Changes

Zenotech Laboratories reports Q3FY26 net profit of ₹192.56 lakhs, appoints new independent director, and reconstitutes board committees following completion of director's tenure.

23 Jan 2026

co actions results

Zenotech Laboratories Reports Board Meeting Outcome and Financial Results for Quarter Ended September 30, 2025

Zenotech Laboratories Limited held a Board of Directors meeting on October 31, 2025, approving unaudited standalone financial results for the quarter and half-year ended September 30, 2025. The company reported revenue from operations of Rs. 1,023.19 lakhs for the quarter, compared to Rs. 874.60 lakhs in the same period last year. For the half-year, revenue reached Rs. 1,887.10 lakhs versus Rs. 1,764.09 lakhs previously. The company recorded a profit before tax of Rs. 120.85 lakhs for the quarter. Total assets stood at Rs. 10,892.39 lakhs as of September 30, 2025. The company reversed excess provision of Rs. 4.97 lakhs related to export obligation settlement, reported as exceptional items. Additionally, accounting adjustments of Rs. 190.49 lakhs were made for tax liabilities under section 115BAA of the Income Tax Act. The financial results underwent limited review by statutory auditors and were approved by the Audit Committee.

31 Oct 2025

earnings

Zenotech Laboratories Reports Q1 FY2026 Results, Appoints New Statutory Auditors

Zenotech Laboratories Limited approved its unaudited standalone financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs 863.91 lakhs compared to Rs 889.49 lakhs in the same quarter last year, while total income remained relatively stable at Rs 1,023.16 lakhs versus Rs 1,024.96 lakhs. Net profit for the quarter was Rs 98.96 lakhs, down from Rs 128.97 lakhs in the corresponding quarter of the previous year. Earnings per share stood at Rs 0.16 compared to Rs 0.21 in the same period last year. The Board also approved the appointment of M/s. G S K A & Co. as new statutory auditors for a five-year term, replacing M/s. PKF Sridhar & Santhanam LLP who will complete their two consecutive terms. The appointment is subject to shareholder approval at the 36th Annual General Meeting scheduled for September 26, 2025. The company operates solely in the pharmaceuticals segment and generates other operating income through rentals for biotech facility and equipment leased to Sun Pharmaceutical Industries Limited.

28 Jul 2025

earnings

Zenotech Laboratories: Q3 Profit Drops 49.7% Despite Revenue Growth

Zenotech Laboratories reported Q3 FY25 results with revenue up 2.74% YoY to ₹11.24 crore, but profit fell 49.7% YoY to ₹1.69 crore. EPS decreased 60% to ₹0.22. Operating income rose 35.82% QoQ but declined 22.44% YoY.

30 Jan 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800